Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
AstraZeneca
Merck
Express Scripts
Dow

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Polidocanol - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for polidocanol and what is the scope of freedom to operate?

Polidocanol is the generic ingredient in two branded drugs marketed by Chemisch Fbrk Krsslr and Provensis, and is included in two NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Polidocanol has one hundred and eighty-six patent family members in thirty-nine countries.

Two suppliers are listed for this compound.

Summary for polidocanol
International Patents:186
US Patents:14
Tradenames:2
Applicants:2
NDAs:2
Suppliers / Packagers: 2
Bulk Api Vendors: 33
Clinical Trials: 19
Patent Applications: 2,047
Formulation / Manufacturing:see details
DailyMed Link:polidocanol at DailyMed
Recent Clinical Trials for polidocanol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Melanoma Institute AustraliaPhase 2
Societa Italiana di Chirurgia ColoRettalePhase 2
SICCR - Gaetano GalloPhase 2

See all polidocanol clinical trials

Pharmacology for polidocanol
Drug ClassSclerosing Agent
Mechanism of ActionSclerosing Activity
Physiological EffectVascular Sclerosing Activity
Synonyms for polidocanol
2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
3,6,9,12,15,18,21,24,27-Nonaoxanonatriacontan-1-ol
3055-99-0
73579-17-6
9043-30-5
95297-49-7
AC1LCVC1
AEO-9
Aethoxy-sklerol
AKOS028108701
AN-6543
API0005051
Asclera
C12E9
C13493
CAS-3055-99-0
CHEBI:46859
CHEMBL1231723
CTK1C2495
DB06811
Detergent Screening Solution 23/Fluka kit no 66317
DODECYL NONA ETHYLENE GLYCOL ETHER
Dodecyl nonaethylene glycol ether
Dodecylnonaglycol
Dodecylnonaoxyethylene glycol monoether
DSSTox_CID_19721
DSSTox_GSID_39721
DSSTox_RID_79436
DTXSID5039721
EINECS 221-284-4
genapol X 080
genapol X-080
Genapol X080
GK9185
J-018016
KS-00000Y0K
laureth-9
Macrogol 9 lauryl ether
MFCD00043375
MFCD00163738
MolPort-003-935-762
NCGC00166290-01
NCGC00166290-02
NCGC00166290-03
Nonaethylene glycol monododecyl ether
Nonaethylene glycol monododecyl ether, nonionic surfactant
nonaethylene glycol monolauryl ether
Nonaethyleneglycol monododecyl ether 1 mM solution
Nonaethyleneglycol monododecyl ether solution
Oligoethylene glycol monoalkyl ether
ONJQDTZCDSESIW-UHFFFAOYSA-N
PEG-9 lauryl ether
POELE
Polidocanol [INN:DCF:JAN]
Poly(oxy-1,2-ethanediyl),a-isotridecyl-w-hydroxy-
Polydocanol
POLYDOCANOL; THESIT
Polyethylene glycol 450 lauryl ether
Polyethylene glycol monoalkyl ether
Polyethylene glycol monododecyl ether (average polymer, n = 9; nonaethylene glycol monododecyl ether)
Polyethylene glycol monododecyl ether (average polymer, n = 9)
Polyethylene glycol monoisotridecyl ether
Polyoxyethylen-9-laurylether
Polyoxyethylene (9) lauryl ether
Polyoxyethylene 9 lauryl ether
Polyoxyl 9 lauryl ether
SCHEMBL25580
SR-01000944476
SR-01000944476-1
Tox21_112394
Tox21_112394_1
VARITHENA
ZINC8214662

US Patents and Regulatory Information for polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Merck
Express Scripts
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.